Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer-Reference-Cited by-同舟云学术

Antibody-drug conjugates targeting DDR1 as a novel strategy for treatment of breast cancer

Published:2024-08-09 Issue: Volume: Page:1-10
ISSN:1061-186X
Container-title:Journal of Drug Targeting
language:en
Short-container-title:Journal of Drug Targeting

Author:

Tao Yiran¹,Lu Ying²,Xue Ting²³,Lai Qinhuai⁴,Song Hengrui²,Chen Xiaofeng³,Guo Cuiyu²³,Yang Jinliang³,Wang Yuxi²⁵

Affiliation:

1. West China-California Research Center for Predictive Intervention Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China

2. Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China

3. State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China

4. Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China

5. Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China

Funder

the National Natural Science Foundation of China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1061186X.2024.2386621

Reference29 articles.

1. Global trends and forecasts of breast cancer incidence and deaths

2. Targeting HER2-positive breast cancer: advances and future directions

3. Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy

4. New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development

5. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2